Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2015 2
2016 2
2018 1
2019 1
2020 1
2021 2
2022 8
2023 5
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice.
Tanaka S, Hikita H, Tatsumi T, Sakamori R, Nozaki Y, Sakane S, Shiode Y, Nakabori T, Saito Y, Hiramatsu N, Tabata K, Kawabata T, Hamasaki M, Eguchi H, Nagano H, Yoshimori T, Takehara T. Tanaka S, et al. Among authors: nozaki y. Hepatology. 2016 Dec;64(6):1994-2014. doi: 10.1002/hep.28820. Epub 2016 Oct 21. Hepatology. 2016. PMID: 27637015
Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
Tahata Y, Hikita H, Mochida S, Enomoto N, Ido A, Kuroda H, Miki D, Kurosaki M, Hiasa Y, Sakamori R, Kawada N, Yamashita T, Suda G, Yatsuhashi H, Yoshiji H, Kato N, Takami T, Nakao K, Matsuura K, Asahina Y, Itoh Y, Tateishi R, Nakamoto Y, Kakazu E, Terai S, Shimizu M, Ueno Y, Akuta N, Miyazaki M, Nozaki Y, Kabayama M, Sobue S, Moriuchi A, Miyaki T, Kodama T, Tatsumi T, Yamada T, Takehara T. Tahata Y, et al. Among authors: nozaki y. J Gastroenterol. 2023 Dec;58(12):1211-1221. doi: 10.1007/s00535-023-02039-x. Epub 2023 Oct 13. J Gastroenterol. 2023. PMID: 37831182 Free PMC article.
Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.
Matsumae T, Kodama T, Myojin Y, Maesaka K, Sakamori R, Takuwa A, Oku K, Motooka D, Sawai Y, Oshita M, Nakabori T, Ohkawa K, Miyazaki M, Tanaka S, Mita E, Tawara S, Yakushijin T, Nozaki Y, Hagiwara H, Tahata Y, Yamada R, Hikita H, Tatsumi T, Takehara T. Matsumae T, et al. Among authors: nozaki y. Cancers (Basel). 2022 Jul 11;14(14):3367. doi: 10.3390/cancers14143367. Cancers (Basel). 2022. PMID: 35884434 Free PMC article.
Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
Maesaka K, Sakamori R, Yamada R, Doi A, Tahata Y, Ohkawa K, Oshita M, Miyazaki M, Yakushijin T, Nozaki Y, Matsumoto K, Tanaka S, Kaneko A, Iio S, Nawa T, Yamada Y, Morishita N, Usui T, Hiramatsu N, Doi Y, Sakakibara M, Imanaka K, Yoshida Y, Kodama T, Hikita H, Tatsumi T, Takehara T. Maesaka K, et al. Among authors: nozaki y. PLoS One. 2023 Feb 7;18(2):e0281459. doi: 10.1371/journal.pone.0281459. eCollection 2023. PLoS One. 2023. PMID: 36749777 Free PMC article.
Clinical factors associated with the therapeutic efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter prospective observational study.
Kai M, Hikita H, Kazuki M, Tahata Y, Shinkai K, Doi A, Ohkawa K, Miyazaki M, Ishida H, Matsumoto K, Nozaki Y, Yakushijin T, Sakamori R, Kaneko A, Iio S, Nawa T, Kakita N, Morishita N, Hiramatsu N, Usui T, Imanaka K, Doi Y, Sakakibara M, Yoshida Y, Oze T, Kodama T, Tatsumi T, Takehara T. Kai M, et al. Among authors: nozaki y. PLoS One. 2024 Jan 2;19(1):e0294590. doi: 10.1371/journal.pone.0294590. eCollection 2024. PLoS One. 2024. PMID: 38165900 Free PMC article.
Prognostic impact of worsening of esophageal varices after balloon-occluded retrograde transvenous obliteration.
Shinkai K, Sakamori R, Yamada R, Tahata Y, Nozaki Y, Matsumoto K, Tawara S, Fukuda K, Yoshida Y, Tanaka S, Ito T, Doi Y, Iio S, Sakakibara M, Nakanishi F, Kodama T, Hikita H, Tatsumi T, Takehara T. Shinkai K, et al. Among authors: nozaki y. J Gastroenterol Hepatol. 2022 Jun;37(6):1148-1155. doi: 10.1111/jgh.15853. Epub 2022 Apr 26. J Gastroenterol Hepatol. 2022. PMID: 35430734
Interleukin-6 Is a Circulating Prognostic Biomarker for Hepatocellular Carcinoma Patients Treated with Combined Immunotherapy.
Myojin Y, Kodama T, Sakamori R, Maesaka K, Matsumae T, Sawai Y, Imai Y, Ohkawa K, Miyazaki M, Tanaka S, Mita E, Tawara S, Yakushijin T, Nozaki Y, Hagiwara H, Tahata Y, Yamada R, Hikita H, Tatsumi T, Takehara T. Myojin Y, et al. Among authors: nozaki y. Cancers (Basel). 2022 Feb 10;14(4):883. doi: 10.3390/cancers14040883. Cancers (Basel). 2022. PMID: 35205631 Free PMC article.
Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral.
Matsumae T, Kodama T, Tahata Y, Myojin Y, Doi A, Nishio A, Yamada R, Nozaki Y, Oshita M, Hiramatsu N, Morishita N, Ohkawa K, Hijioka T, Sakakibara M, Doi Y, Kakita N, Yakushijin T, Sakamori R, Hikita H, Tatsumi T, Takehara T. Matsumae T, et al. Among authors: nozaki y. Cancers (Basel). 2023 Jan 11;15(2):463. doi: 10.3390/cancers15020463. Cancers (Basel). 2023. PMID: 36672412 Free PMC article.
Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.
Shirai K, Hikita H, Sakamori R, Doi A, Tahata Y, Sakane S, Kamada Y, Murai K, Nishio A, Yamada R, Kodama T, Nozaki Y, Kakita N, Ishida H, Nakanishi F, Morishita N, Imanaka K, Sakakibara M, Tatsumi T, Miyoshi E, Takehara T. Shirai K, et al. Among authors: nozaki y. PLoS One. 2022 Dec 21;17(12):e0279416. doi: 10.1371/journal.pone.0279416. eCollection 2022. PLoS One. 2022. PMID: 36542633 Free PMC article.
22 results